首页|期刊导航|Genes & Diseases|N6-methyladenosine-modified circLPAR3 drives docetaxel resistance in prostate cancer by suppressing ferroptosis through the PCBP2/CHAC1 axis

N6-methyladenosine-modified circLPAR3 drives docetaxel resistance in prostate cancer by suppressing ferroptosis through the PCBP2/CHAC1 axisOA

中文摘要

Epigenetic mechanisms represented by N6-methyladenosine(m6A)modifications and circular RNAs(circRNAs)regulate chemotherapy resistance in prostate cancer(PCa).Here,we stuided the role of m6A-modified circLPAR3 in assisting docetaxel(DTX)resistance in PCa and the mechanism of its regulatory function.The expression of circLPAR3 was higher in all three drug-resistant cell lines than in the corresponding parental cell lines and was mainly localized in the cytoplasm.The m6A modification and stability enhancement of circLPAR3 by the METTL3/IGF2BP2 axis was primarily determined by expression assays,stability assays,and mass spectrometry.Functionally,circLPAR3 reduced the sensitivity of PCa cells to DTX and promoted PCa proliferation in a DTX environment.In addition,circLPAR3 reduced cytotoxicity by inhibiting the DTX-induced ferroptosis effect.Mechanistically,circLPAR3 downregulated the expression of CHAC1,an emerging driver of ferroptosis.PCBP2 was identified as a mediating RNA-binding protein between circLPAR3 and CHAC1.On the one hand,it shares a very high binding phase with circLPAR3 without interfering with each other’s expression;on the other hand,it increases mRNA stability by binding to the 3′UTR of CHAC1,which is interfered by circLPAR3.In conclusion,m6A-modified circLPAR3 inhibits CHAC1 expression by competitively binding to PCBP2,ultimately conferring docetaxel resistance to PCa.

Yetao Zhang;Yuxiang Dong;Kai Li;Tong Zhao;Yongshan Li;Mingyang Pang;Yong Wei;Bing Yao;Qingyi Zhu

Department of Urology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210011,ChinaDepartment of Urology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210011,ChinaDepartment of Urology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210011,ChinaDepartment of Urology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210011,ChinaDepartment of Urology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210011,ChinaDepartment of Urology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210011,ChinaDepartment of Urology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210011,ChinaDepartment of Medical Genetics,Nanjing Medical University,Nanjing,Jiangsu 211166,ChinaDepartment of Urology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210011,China

医药卫生

CHAC1ChemoresistancecircLPAR3DocetaxelFerroptosisN6-methyladenosineProstate cancer

《Genes & Diseases》 2026 (6)

P.598-614,17

supported by the Scientific Research Project of Jiangsu Provincial Health and Wellness Commission(China)(No.ZD2021028)Jiangsu Provincial Postgraduate Research Innovation Program(China)(No.KYCX23_1926).

10.1016/j.gendis.2025.101816

评论